Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00668733|
Recruitment Status : Completed
First Posted : April 29, 2008
Results First Posted : July 13, 2010
Last Update Posted : July 20, 2010
|Condition or disease|
This is a Phase 3 longitudinal and observational study. Subjects who previously enrolled in studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705 and were completely cleared of their AK lesions in the selected treatment area at the end-of-study visit will return for follow-up visits at 6 and 12 months after the EOS visit or until a recurrence of AKs.
The NCT numbers for the above mentioned studies are:
NCT00603798 - for Studies GW01-0703 and GW01-0705
NCT00605176 for Studies GW01-0702 and GW01-0704
|Study Type :||Observational|
|Actual Enrollment :||179 participants|
|Official Title:||Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
- Number of Participants With Recurrence of AK Lesions [ Time Frame: Up to one year ]The primary efficacy variable in this study was the absence of AK lesions(sustained clearance rate) in the previously treated area.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00668733
|Study Director:||Sharon Levy, MD||Graceway Pharmaceuticals, LLC|